STAR IN THE NEWS​

Press Releases

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

  • Purohit Navigation
  • January 6, 2025
SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

Star Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

  • Purohit Navigation
  • January 2, 2025
SOUTH SAN FRANCISCO, CA, January 2, 2025 – Star Therapeutics, a clinical stage biotechnology company.

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

  • Purohit Navigation
  • December 9, 2024
SOUTH SAN FRANCISCO, CA, December 9, 2024 – Star Therapeutics, a clinical stage biotechnology company.

Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)

  • Purohit Navigation
  • June 26, 2024
SOUTH SAN FRANCISCO, CA, June 26, 2024 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

Star Therapeutics Appoints Scott Robertson, MBA, as Chief Business Officer and Chief Financial Officer

  • Purohit Navigation
  • January 3, 2024
SOUTH SAN FRANCISCO, CA, January 3, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

Star Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

  • Purohit Navigation
  • January 2, 2024
SOUTH SAN FRANCISCO, CA, January 2, 2024 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

Star Therapeutics Appoints Matthew Fust as Independent Director and Audit Chair

  • Purohit Navigation
  • December 5, 2023
SOUTH SAN FRANCISCO, CA, December 5, 2023 – Star Therapeutics, a biotechnology company interrogating novel biology to develop life-changing therapies...

Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

  • Purohit Navigation
  • September 5, 2023
SOUTH SAN FRANCISCO, CA, September 5, 2023 – Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics...

Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease

  • Purohit Navigation
  • May 23, 2023
SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies...

Vega Therapeutics Initiates Clinical Trial Program for VGA039, a First-in-Class Antibody Therapy for von Willebrand Disease

  • Purohit Navigation
  • April 6, 2023
Phase 1 Clinical Trial Advances with First Subject Dosed in the E.U. and IND Accepted in the U.S...

News Coverage

Breaking new ground in von Willebrand disease treatment

  • Jules Adam, Labiotech
  • January 9, 2025
Earlier this week, Star Therapeutics’ von Willebrand disease candidate – VGA039 – was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). While it is the most common inherited bleeding disorder and affects about 1% of the population, you don’t hear about von Willebrand disease every day. With Star Therapeutics’ candidate getting some recognition from the FDA...

Promising Star formations draw investors in $90M oversubscribed series C

  • Jennifer Boggs, BioWorld
  • September 5, 2023
Star Therapeutics Inc. brought on board six new investors in its oversubscribed $90 million series C round, raising the company’s total funding to more than $190 million since its founding in 2018 to advance in-house drug discovery efforts via formation of portfolio companies. Since emerging from stealth in early...

Stars align as ex-True North team nabs another $90M to build out biotech constellation

  • Kyle LaHucik, Endpoints
  • September 5, 2023
Star Therapeutics, which created two antibody-focused biotech startups with more in the works, has now reeled in a $90 million Series C. The round, disclosed Tuesday morning, brings the Bay Area biotech’s total financing to more than $190 million since emerging from Westlake Village BioPartners in early 2022. Star’s biotech startups Vega Therapeutics and Electra Therapeutics...

Investors shower Star Therapeutics with $90M for constellation of biotechs, antibody therapies

  • Gabrielle Masson, Fierce Biotech
  • September 5, 2023
Investors have showered Star Therapeutics with $90 million to grow its portfolio companies and develop new antibody drugs for diseases with high unmet need. Sofinnova Investments led the oversubscribed series C round and was joined by new investors Qatar Investment Authority, Catalio Capital Management, Agent Capital, Soleus Capital and NYBC Ventures alongside all seven...

Asked and Answered: Follow the Biology

  • By Damian Doherty, Inside Precision Medicine
  • December 23, 2022
Adam Rosenthal is the CEO and founder of Star Therapeutics, a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible. The company’s engine for innovation starts with identifying multiple rare diseases that share a common biology and then discovering novel therapeutics that can treat these diseases with a single therapy. Star consists…

Presentations

A PHASE IA STUDY OF VGA039, A PROTEIN S–TARGETING MONOCLONAL ANTIBODY, IN INDIVIDUALS WITH VON WILLEBRAND DISEASE DEMONSTRATES CONCENTRATION-DEPENDENT INCREASES IN THROMBIN GENERATION FOR REDUCING BLEEDING

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3981

DIAGNOSIS AND DISEASE BURDEN OF VON WILLEBRAND DISEASE IN A LARGE US POPULATION–BASED DATASET

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3980

DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH VON WILLEBRAND DISEASE IN A LARGE US POPULATION-BASED DATASET

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3978

Factor VIII Coagulant Activity (FVIII:C) as an Independent Predictor of Bleeding across Different Subtypes of Von Willebrand Disease (VWD)

  • Purohit Navigation
  • December 9, 2024
ASH 2024 ABSTRACT #3982